CEBINA Announces Positive Results of a Phase 2 Clinical Study with COVID-19 patients and Azelastine Nasal Spray Published in a Peer-Reviewed Scientific Journal
CEBINA GmbH, Central European Biotech Incubator and Accelerator, today announces the publication of the positive results of a Phase 2 clinical study that tested azelastine nasal spray as a new approach for reducing viral load in the nose of SARS-CoV-2 positive patients in the peer-reviewed journal Scientific Reports (1). Vaccines have been a useful […]
Continue Reading